Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03193853
Title TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Baylor Research Institute

triple-receptor negative breast cancer


Cisplatin + Nab-paclitaxel

Sapanisertib + Serabelisib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.